Minireview: 12-lipoxygenase and islet β-cell dysfunction in diabetes

Molecular Endocrinology

Volumn 29, Issue 6, 2015, Pages 791-800

  Tersey, Sarah A ^a   Bolanis, Esther ^a   Holman, Theodore R ^b   Maloney, David J ^c   Nadler, Jerry L ^d   Mirmira, Raghavendra G ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONIC ACID; BAICALEIN; LIPOXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; TRANSCRIPTION FACTOR NRF2; ZILEUTON; MOLECULAR LIBRARY;

ANIMAL GENETICS; ARTICLE; AUTOIMMUNITY; CELL DEATH; CELL DEDIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; GENE DELETION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN GENETICS; HYPERGLYCEMIA; IMMUNOREACTIVITY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; METABOLIC DISORDER; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PLEIOTROPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGY; THERAPEUTIC USE;

ANIMALIA; MUS;

ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; DIABETES MELLITUS; HUMANS; INFLAMMATION; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL; SMALL MOLECULE LIBRARIES;

EID: 84930827504     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1041     Document Type: Article

References (121)

1. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32:287–294.
2. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013.
3. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884-1890.
4. Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778-1786.
5. Forlenza GP, Rewers M. The epidemic of type 1 diabetes: what is it telling us? Curr Opin Endocrinol Diabetes Obes. 2011;18:248-251.
6. Lawrence JM, Imperatore G, Dabelea D, et al. Trends in incidence of type 1 diabetes among non-Hispanic white youth in the U.S., 2002-2009. Diabetes. 2014;63(11):3938-3945.
7. Hanas R, John G, International HBA1c Consensus Committee. 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care. 2010;33:1903-1904.
8. Lawes CM, Parag V, Bennett DA, et al. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care. 2004;27:2836-2842.
9. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes. 1993; 42(11):1663-1672.
10. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS, DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010;59:679-685.
11. Ize-Ludlow D, Lightfoot YL, Parker M, et al. Progressive erosion of β-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes. Diabetes. 2011;60:2086-2091.
12. Tersey SA, Nishiki Y, Templin AT, et al. Islet β-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nono-bese diabetic mouse model. Diabetes. 2012;61:818-827.
13. Velloso LA, Eizirik DL, Cnop M. Type 2 diabetes mellitus-an autoimmune disease? Nat Rev Endocrinol. 2013;9:750-755.
14. Evans-Molina C, Hatanaka M, Mirmira RG. Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus. Diabetes Obes Metab. 2013;15(suppl 3):159-169.
15. Imai Y, Dobrian AD, Morris MA, Nadler JL. Islet inflammation: a unifying target for diabetes treatment? Trends Endocrinol Metab. 2013;24:351-360.
16. Nishimura S, Manabe I, Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. Discov Med. 2009;8:55-60.
17. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914-920.
18. Morris DL, Cho KW, Delproposto JL, et al. Adipose tissue macrophages function as antigen-presenting cells and regulate adipose tissue CD4+ T cells in mice. Diabetes. 2013;62(8):2762-2772.
19. Morris DL, Singer K, Lumeng CN. Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr Metab Care. 2011;14:341-346.
20. Brooks-Worrell BM, Boyko EJ, Palmer JP. Impact of islet autoimmunity on the progressive β-cell functional decline in type 2 diabetes. Diabetes Care. 2014;37(12):3286-3293.
21. Brooks-Worrell BM, Iyer D, Coraza I, et al. Islet-specific T-cell responses and proinflammatory monocytes define subtypes of au-toantibody-negative ketosis-prone diabetes. Diabetes Care. 2013; 36(12):4098-4103.
22. Eguchi K, Manabe I, Oishi-Tanaka Y, et al. Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab. 2012;15:518-533.
23. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007;56: 2356-2370.
24. Weir GC, Bonner-Weir S. Five stages of evolving β-cell dysfunction during progression to diabetes. Diabetes. 2004;53(suppl 3):S16-S21.
25. White MG, Marshall HL, Rigby R, et al. Expression of mesenchymal and a-cell phenotypic markers in islet β-cells in recently diagnosed diabetes. Diabetes Care. 2013;36(11):3818-3820.
26. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell. 2012;150(6):1223-1234.
27. Guo S, Dai C, Guo M, et al. Inactivation of specific β cell transcription factors in type 2 diabetes. J Clin Invest. 2013;123(8):3305-3316.
28. Atkinson MA, Bluestone JA, Eisenbarth GS, et al. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes. 2011;60:1370-1379.
29. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5:219-226.
30. Maganti A, Evans-Molina C, Mirmira RG. From immunobiology to β-cell biology: the changing perspective on type 1 diabetes. Islets. 2014;6.
31. O’Sullivan-Murphy B, Urano F. ER stress as a trigger for β-cell dysfunction and autoimmunity in type 1 diabetes. Diabetes. 2012; 61:780-781.
32. Soleimanpour SA, Stoffers DA. The pancreatic β cell and type 1 diabetes: innocent bystander or active participant? Trends Endocrinol. Metab. 2013;24(7):324-331.
33. Keskinen P, Korhonen S, Kupila A, et al. First-phase insulin response in young healthy children at genetic and immunological risk for type I diabetes. Diabetologia. 2002;45:1639-1648.
34. Engin F, Yermalovich A, Nguyen T, et al. Restoration of the unfolded protein response in pancreatic β cells protects mice against type 1 diabetes. Sci Transl Med. 2013;5:211ra156.
35. Marhfour I, Lopez XM, Lefkaditis D, et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia. 2012;55:2417-2420.
36. Powell WS, RokachJ. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochim Biophys Acta. 2015;1851(4):340-355.
37. Haeggström JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev. 2011; 111(10):5866-5898.
38. Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygen-ase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta. 2015;1851(4):331-339.
39. Mehrabian M, Allayee H, Wong J, et al. Identification of 5-lipoxy-genase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91(2):120-126.
40. Zhao L, Moos MP, Gräbner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004;10(9):966-973.
41. Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS. 5-Li-poxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes. 2008;57(5):1387-1393.
42. Morgan RO, Laychock SG. Biosynthesis of peptidyl leukotrienes and other lipoxygenase products by rat pancreatic islets. Comparison with macrophages and neutrophils. Prostaglandins. 1988; 35(4):609-623.
43. Persaud SJ, Muller D, Belin VD, et al. The role of arachidonic acid and its metabolites in insulin secretion from human islets of lang-erhans. Diabetes. 2007;56:197-203.
44. Mehrabian M, Schulthess FT, Nebohacova M, et al. Identification of ALOX5 as a gene regulating adiposity and pancreatic function. Diabetologia. 2008;51(6):978-988.
45. Chen XS, Brash AR, Funk CD. Purification and characterization of recombinant histidine-tagged human platelet 12-lipoxygenase ex-pressed in a baculovirus/insect cell system. Eur J Biochem. 1993; 214(3):845-852.
46. Chen M, Yang ZD, Smith KM, Carter JD, Nadler JL. Activation of 12-lipoxygenase in proinflammatory cytokine-mediated β cell toxicity. Diabetologia. 2005;48:486-495.
47. Funk CD, Cyrus T. 12/15-lipoxygenase, oxidative modification of LDL and atherogenesis. Trends Cardiovasc Med. 2001;11:116-124.
48. Kühn H, O’Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res. 2006;45:334-356.
49. Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, Nadler JL. 12-Lipoxygenase products reduce insulin secretion and β-cell viability in human islets. J Clin EndocrinolMetab. 2010; 95:887-893.
50. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:1542-1548.
51. Nieves D, Moreno JJ. Enantioselective effect of 12(S)-hydroxyeico-satetraenoic acid on 3T6 fibroblast growth through ERK 1/2 and p38 MAPK pathways and cyclin D1 activation. Biochem Pharmacol. 2008;76(5):654-661.
52. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA. 1989;86(3):1046-1050.
53. Tang DG, Honn KV. 12-Lipoxygenase, 12(S)-HETE, and cancer metastasis. Ann NY Acad Sci. 1994;744:199-215.
54. Wen Y, Gu J, Chakrabarti SK, et al. The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-a in macrophages. Endocrinology. 2007;148:1313-1322.
55. Han X, Chen S, Sun Y, Nadler JL, Bleich D. Induction of cycloox-ygenase-2 gene in pancreatic β-cells by 12-lipoxygenase pathway product 12-hydroxyeicosatetraenoic acid. Mol Endocrinol. 2002; 16:2145-2154.
56. Aliberti J, Hieny S, Reis e Sousa C, Serhan CN, Sher A. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat Immunol. 2002;3(1):76-82.
57. Middleton MK, Rubinstein T, Puré E. Cellular and molecular mechanisms of the selective regulation of IL-12 production by 12/ 15-lipoxygenase. J Immunol. 2006;176(1):265-274.
58. Zhao L, Cuff CA, Moss E, et al. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem. 2002;277(38):35350-35356.
59. Laybutt DR, Sharma A, Sgroi DC, Gaudet J, Bonner-Weir S, Weir GC. Genetic regulation of metabolic pathways in β-cells disrupted by hyperglycemia. J Biol Chem. 2002;277:10912-10921.
60. Natarajan R, Gerrity RG, Gu JL, Lanting L, Thomas L, Nadler JL. Role of 12-lipoxygenase and oxidant stress in hyperglycaemia-in-duced acceleration of atherosclerosis in a diabetic pig model. Diabetologia. 2002;45:125-133.
61. Natarajan R, Gu JL, Rossi J, et al. Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc Natl Acad Sci USA. 1993;90:4947-4951.
62. Tokuyama Y, Sturis J, DePaoli AM, et al. Evolution of β-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes. 1995;44: 1447-1457.
63. Tersey SA, Maier B, Nishiki Y, Maganti AV, Nadler JL, Mirmira RG. 12-Lipoxygenase promotes obesity-induced oxidative stress in pancreatic islets. Mol Cell Biol. 2014;34(19):3735-3745.
64. Chakrabarti SK, Wen Y, Dobrian AD, et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab. 2011;300: E175-E187.
65. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL. 12/15-lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity. 2009;17:1657-1663.
66. Ferré N, Martínez-Clemente M, López-Parra M, et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G553-G562.
67. Martínez-Clemente M, Ferré N, Titos E, et al. Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology. 2010;52:1980-1991.
68. Taha AY, Gao F, Ramadan E, Cheon Y, Rapoport SI, Kim H-W. Upregulated expression of brain enzymatic markers of arachidonic and docosahexaenoic acid metabolism in a rat model of the metabolic syndrome. BMC Neurosci. 2012;13:131.
69. George J, Afek A, Shaish A, et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation. 2001;104:1646-1650.
70. Huo Y, Zhao L, Hyman MC, et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-defi-cient mice. Circulation. 2004;110:2024-2031.
71. Nunemaker CS, Chen M, Pei H, et al. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet. Am J Physiol Endocrinol Metab. 2008;295:E1065-E1075.
72. Sears DD, Miles PD, Chapman J, et al. 12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PLoS One. 2009;4: e7250.
73. Lieb DC, Brotman JJ, Hatcher MA, et al. Adipose tissue 12/15 lipoxygenase pathway in human obesity and diabetes. J Clin End-crinol Metab. 2014;99(9):E1713-E1720.
74. Cole BK, Morris MA, Grzesik WJ, Leone KA, Nadler JL. Adipose tissue-specific deletion of 12/15-lipoxygenase protects mice from the consequences of a high-fat diet. Mediat. Inflamm. 2012;2012: 851798.
75. Fu Y, Luo N, Lopes-Virella MF. Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J Lipid Res. 2000;41:2017-2023.
76. Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001;7:699-705.
77. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005;23:447-485.
78. Reddy S, Liu W, Elliott RB. Distribution of pancreatic macrophages preceding and during early insulitis in young NOD mice. Pancreas. 1993;8:602-608.
79. Green-Mitchell SM, Tersey SA, Cole BK, et al. Deletion of 12/15-lipoxygenase alters macrophage and islet function in NOD-Alox15(null) mice, leading to protection against type 1 diabetes development. PLoS One. 2013;8:e56763.
80. Bleich D, Chen S, Gu JL, Nadler JL. The role of 12-lipoxygenase in pancreatic -cells (review). Int J Mol Med. 1998;1:265-272.
81. Bleich D, Chen S, Gu JL, et al. Interleukin-1 β regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells. Endocrinology. 1995;136:5736-5744.
82. Shannon VR, Ramanadham S, Turk J, Holtzman MJ. Selective expression of an arachidonate 12-lipoxygenase by pancreatic islet β-cells. Am J Physiol. 1992;263:E828-E836.
83. Ma Z, Ramanadham S, Corbett JA, et al. Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism. J Biol Chem. 1996;271:1029-1042.
84. Kawajiri H, Zhuang D, Qiao N, et al. Expression of arachidonate 12-lipoxygenase in rat tissues: a possible role in glucagon secretion. J Histochem Cytochem. 2000;48(10):1411-1419.
85. Grzesik WJ, Nadler JL, Machida Y, Nadler JL, Imai Y, Morris MA. Expression pattern of 12-lipoxygenase in human islets with type 1 diabetes and type 2 diabetes. J Clin Endocrinol Metab. 2015; 100(3):E387-E395.
86. El-Gohary Y, Tulachan S, Wiersch J, et al. A Smad signaling network regulates islet cell proliferation. Diabetes. 2014;63(1):224-236.
87. Bleich D, Chen S, Zipser B, Sun D, Funk CD, Nadler JL. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. J Clin Invest. 1999;103:1431-1436.
88. Wang Z, Gleichmann H. GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozo-tocin in mice. Diabetes. 1998;47:50-56.
89. Calderon B, Suri A, Miller MJ, Unanue ER. Dendritic cells in islets of Langerhans constitutively present β cell-derived peptides bound to their class II MHC molecules. Proc Natl Acad Sci USA. 2008; 105:6121-6126.
90. Luki ML, Stosi-Grujici S, Shahin A. Effector mechanisms in low-dose streptozotocin-induced diabetes. Dev Immunol. 1998;6:119-128.
91. Maier B, Ogihara T, Trace AP, et al. The unique hypusine modification of eIF5A promotes islet β cell inflammation and dysfunction in mice. J Clin Invest. 2010;120:2156-2170.
92. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med. 1996;20:463-466.
93. Weaver JR, Holman TR, Imai Y, et al. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet β cell dysfunction. Mol Cell Endocrinol. 2012;358(1):88-95.
94. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal. 2007;9:2277-2293.
95. Liu B, Khan WA, Hannun YA, et al. 12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-a in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids. Proc Natl Acad Sci USA. 1995;92(20): 9323-9327.
96. Guo Y, Zhang W, Giroux C, et al. Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxy-eicosatetraenoic acid. J Biol Chem. 2011;286:33832-33840.
97. Shappell SB, Gupta RA, Manning S, et al. 15S-hydroxyeicosatetra-enoic acid activates peroxisome proliferator-activated receptor y and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001;61(2):497-503.
98. Hosoi T, Koguchi Y, Sugikawa E, et al. Identification of a novel human eicosanoid receptor coupled to Gi/o. J Biol Chem. 2002; 277(35):31459-31465.
99. Ramanadham S, Bohrer A, Mueller M, Jett P, Gross RW, Turk J. Mass spectrometric identification and quantitation of arachido-nate-containing phospholipids in pancreatic islets: prominence of plasmenylethanolamine molecular species. Biochemistry. 1993; 32(20):5339-5351.
100. Jones PM, Persaud SJ. Arachidonic acid as a second messenger in glucose-induced insulin secretion from pancreatic β-cells. J Endocrinol. 1993;137(1):7-14.
101. Turk J, Gross RW, Ramanadham S. Amplification of insulin secretion by lipid messengers. Diabetes. 1993;42(3):367-374.
102. Kimple ME, Keller MP, Rabaglia MR, et al. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion. Diabetes. 2013;62(6):1904-1912.
103. Parazzoli S, Harmon JS, Vallerie SN, Zhang T, Zhou H, Robertson RP. Cyclooxygenase-2, not microsomal prostaglandin E syn-thase-1, is the mechanism for interleukin-1β-induced prostaglandin E2 production and inhibition of insulin secretion in pancreatic islets. J Biol Chem. 2012;287(38):32246-32253.
104. Tran PO, Gleason CE, Poitout V, Robertson RP. Prostaglandin E2 mediates inhibition of insulin secretion by interleukin-1β. J Biol Chem. 1999;274(44):31245-31248.
105. Jang I, Park S, Cho JW, Yigitkanli K, van Leyen K, Roth J. Genetic ablation and short-duration inhibition of lipoxygenase results in increased macroautophagy. Exp Cell Res. 2014;321(2):276-287.
106. Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract. 2007;61(4):663-676.
107. Deschamps JD, Kenyon VA, Holman TR. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg Med Chem. 2006;14:4295-4301.
108. Amagata T, Whitman S, Johnson TA, et al. Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003;66:230-235.
109. Cichewicz RH, Kenyon VA, Whitman S, et al. Redox inactivation of human 15-lipoxygenase by marine-derived meroditerpenes and synthetic chromanes: archetypes for a unique class of selective and recyclable inhibitors. J Am Chem Soc. 2004;126(45):14910-14920.
110. Malterud KE, Rydland KM. Inhibitors of 15-lipoxygenase from orange peel. J Agric Food Chem. 2000;48(11):5576-5580.
111. Moreau RA, Agnew J, Hicks KB, Powell MJ. Modulation of lipoxygenase activity by bacterial hopanoids. J Nat Prod. 1997; 60(4):397-398.
112. Sailer ER, Schweizer S, Boden SE, Ammon HP, Safayhi H. Characterization of an acetyl-11-keto-β-boswellic acid and arachido-nate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem. 1998;256(2):364-368.
113. Segraves EN, Shah RR, Segraves NL, et al. Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004;47(16):4060-4065.
114. Vasquez-Martinez Y, Ohri RV, Kenyon V, Holman TR, Sepúlveda-Boza S. Structure-activity relationship studies of fla-vonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2. Bioorg Med Chem. 2007;15(23):7408-7425.
115. Whitman S, Gezginci M, Timmermann BN, Holman TR. Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase. J Med Chem. 2002;45(12):2659-2661.
116. Kenyon V, Chorny I, Carvajal WJ, Holman TR, Jacobson MP. Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. J Med Chem. 2006;49(4): 1356-1363.
117. Deschamps JD, GautschiJT, Whitman S, etal. Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007;15(22):6900-6908.
118. Kenyon V, Rai G, Jadhav A, et al. Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase. J Med Chem. 2011;54(15):5485-5497.
119. Luci DK, Jameson JB 2nd, Yasgar A, et al. Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl-)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase. J Med Chem. 2014;57(2):495-506.
120. Taylor-Fishwick DA, Weaver J, Glenn L, et al. Selective inhibition of 12-lipoxygenase protects islets and β cells from inflammatory cytokine-mediated β cell dysfunction. Diabetologia. 2015;58(3): 549-557.
121. McDuffie M, Maybee NA, Keller SR, Stevens BK, Germey JC, Morris MA, et al. Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes. Diabetes. 2008;57(1):199-208.